Opioid prescribing in England remains a pressing public health concern. According to the Office for Health Improvement and Disparities, opioid-related deaths have risen steadily over the past decade, and community pharmacists are increasingly recognised as front-line professionals in both prevention and harm reduction.
The scale of opioid prescribing
NHS Business Services Authority data shows that millions of opioid prescriptions are dispensed annually through community pharmacies in England. These range from low-potency codeine combinations for acute pain to long-term morphine, oxycodone, and fentanyl patches for chronic conditions. The sheer volume of dispensing places pharmacists in a unique position to observe patterns — repeated early requests, dose escalation, and multi-prescriber sourcing — that may indicate problematic use.
According to PharmSee's analysis of 1,742 active pharmacy vacancies across 11 sources, the community pharmacy workforce remains under pressure, with dispensing and checking workloads leaving limited time for proactive clinical intervention. Nevertheless, the pharmacist's role in opioid stewardship is expanding.
Identifying dependency red flags
Community pharmacists should be alert to several indicators of problematic opioid use:
| Red flag | What to look for |
|---|---|
| Early refill requests | Patient requests prescription significantly before expected run-out date |
| Dose escalation | Repeated prescriber increases without clear clinical rationale documented |
| Multiple prescribers | Prescriptions from different GPs or walk-in centres for the same class |
| Behavioural changes | Agitation when supply is delayed, requests for specific brands or formulations |
| OTC codeine purchases | Frequent purchases of co-codamol, Nurofen Plus, or Solpadeine alongside prescriptions |
The Pharmaceutical Journal has noted that pharmacists are often the first healthcare professional to notice these patterns, given the frequency of patient contact during dispensing.
The OTC codeine challenge
Over-the-counter codeine-containing products represent a distinct stewardship challenge. Products such as co-codamol 8/500, Nurofen Plus (codeine 12.8mg/ibuprofen 200mg), and Solpadeine Max are available without prescription but carry dependency risk. Under the Human Medicines Regulations 2012, pharmacists must exercise professional judgement when supplying these products and are expected to refuse sale where dependency is suspected.
The GPhC's guidance on responsible supply of OTC codeine-containing medicines emphasises that pharmacists should ask about duration of use, other medicines being taken, and whether a GP has been consulted for the underlying condition.
Naloxone: the emergency antidote
Naloxone (Nyxoid nasal spray or Prenoxad injection) reverses opioid overdose and can be life-saving when administered promptly. In England, community pharmacists can supply naloxone through several routes:
- NHS-commissioned services: Some Integrated Care Boards commission community pharmacies to supply naloxone kits to people at risk of opioid overdose and their families. These are typically provided free of charge to the patient.
- PGD (Patient Group Direction) supply: Where a local PGD is in place, pharmacists can supply naloxone without an individual prescription to eligible individuals.
- Private purchase: Naloxone is a pharmacy (P) medicine and can be sold over the counter without a prescription.
- Drug treatment services: Pharmacies providing supervised consumption or needle exchange often supply naloxone as part of harm reduction packs.
The availability of naloxone through community pharmacy varies by region. Not all ICBs commission this service, creating geographic variation in access that mirrors broader patterns of healthcare provision inequality.
Supervised consumption services
Many community pharmacies provide supervised consumption of methadone or buprenorphine for patients in opioid substitution therapy. According to PharmSee's database of pharmacy services across England, these services form a significant part of the harm reduction infrastructure, particularly in urban areas with higher rates of opioid dependency.
Pharmacists providing supervised consumption develop ongoing clinical relationships with patients and are well-placed to monitor adherence, identify deterioration, and refer to specialist drug treatment services when needed.
What pharmacists can do
Practical steps for community pharmacists engaged in opioid stewardship include:
- Review repeat prescriptions proactively — flag long-term opioid prescriptions for MUR or structured medication review discussions.
- Use the NHSBSA ePACT2 prescribing data — benchmark local opioid prescribing rates against regional and national averages.
- Stock and promote naloxone — ensure naloxone is available and that counter staff know its purpose.
- Train the team — the Centre for Pharmacy Postgraduate Education (CPPE) offers opioid stewardship training modules for pharmacists and technicians.
- Engage with local drug and alcohol services — build referral pathways for patients showing signs of dependency.
The bigger picture
Community pharmacists dispense the medicines, observe the patterns, and see the patients most frequently. That combination makes them indispensable in opioid stewardship — not as enforcers, but as clinicians with both the access and the expertise to intervene early. Explore local pharmacy services or job opportunities in pharmacy on PharmSee.
Sources: OHID opioid data, NHSBSA prescribing statistics, GPhC guidance on OTC codeine supply, Human Medicines Regulations 2012, CPPE opioid stewardship module, PharmSee vacancy database (1,742 active roles as of April 2026).